Sustainability | August 12, 2025
Centrient Pharmaceuticals joins UNGC
Reinforcing commitment to ethical and sustainable growth
Reinforcing commitment to ethical and sustainable growth
The agreement complements other PPAs for Sandoz production sites globally
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Vasograin Plus represents a major advancement in the treatment of migraine
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Celecoxib is a nonsteroidal anti-inflammatory drug
Subscribe To Our Newsletter & Stay Updated
